A Look At Adaptive Biotechnologies (ADPT) Valuation After Q4 2025 Beat And New Pfizer Agreements

Why Adaptive Biotechnologies Stock Is Back in Focus Adaptive Biotechnologies (ADPT) is drawing attention after fourth quarter 2025 results topped analyst expectations, supported by its Minimal ...

Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look

Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale amid strong one-year stock ...
Benzinga.com

What's Going On With Adaptive Biotechnologies Shares Tuesday?

Adaptive reported preliminary, unaudited revenue of approximately $72 million for the fourth quarter of 2025, representing a 51% increase compared to the same period in 2024. Full-year 2025 revenue ...

Adaptive Biotechnologies Insider Sells $1 Million in Stock After a Doubling in Share Price

Adaptive Biotechnologies, a leader in immune-driven diagnostics, reported a notable insider sale after a strong one-year ...
Seeking Alpha

Adaptive Biotechnologies to Report Third Quarter 2025 Financial Results on November 5, 2025

SEATTLE, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...
Seeking Alpha

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...
Hosted on MSN

Adaptive Biotechnologies (ADPT) Price Target Increased by 17.35% to 16.76

) has been revised to $16.76 / share. This is an increase of 17.35% from the prior estimate of $14.28 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...
Benzinga.com

The Analyst Verdict: Adaptive Biotechnologies In The Eyes Of 4 Experts

In the last three months, 4 analysts have published ratings on Adaptive Biotechnologies (NASDAQ:ADPT), offering a diverse range of perspectives from bullish to bearish. The table below provides a ...
Nasdaq

Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?

Shares of Adaptive Biotechnologies (ADPT) have been strong performers lately, with the stock up 30% over the past month. The stock hit a new 52-week high of $13.52 in the previous session. Adaptive ...
Business Insider

Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...
Business Insider

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...